Considerations on antimicrobial prophylaxis in patients with lymphoproliferative diseases: A SEIFEM group position paper

Crit Rev Oncol Hematol. 2021 Feb;158:103203. doi: 10.1016/j.critrevonc.2020.103203. Epub 2020 Dec 31.

Abstract

The therapeutic armamentarium for the treatment of patients with lymphoproliferative diseases has grown considerably over the most recent years, including a large use of new immunotherapeutic agents. As a consequence, the epidemiology of infectious complications in this group of patients is poorly documented, and even more importantly, the potential benefit of antimicrobial prophylaxis remains a matter of debate when considering the harmful effect from the emergence of multidrug resistant pathogens. The present position paper is addressed to all hematologists treating patients affected by lymphoproliferative malignancies with the aim to provide clinicians with a useful tool for the prevention of bacterial, fungal and viral infections.

Keywords: Antimicrobial prophylaxis; Antimicrobial stewardship.; Bacterial; Fungal and viral infections; Lymphoproliferative disorders.

Publication types

  • Review

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Anti-Infective Agents* / therapeutic use
  • Humans
  • Lymphoproliferative Disorders* / drug therapy
  • Lymphoproliferative Disorders* / epidemiology
  • Lymphoproliferative Disorders* / etiology

Substances

  • Anti-Bacterial Agents
  • Anti-Infective Agents